Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1976 1
1977 1
1978 2
1979 2
1980 3
1981 1
1982 1
1983 3
1984 3
1985 5
1986 4
1987 2
1988 5
1989 5
1990 9
1991 9
1992 8
1993 7
1994 5
1995 6
1996 6
1997 7
1998 15
1999 12
2000 12
2001 21
2002 17
2003 16
2004 24
2005 30
2006 26
2007 37
2008 45
2009 56
2010 61
2011 58
2012 79
2013 66
2014 76
2015 70
2016 76
2017 72
2018 84
2019 78
2020 91
2021 98
2022 88
2023 82
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

1,328 results

Results by year

Filters applied: . Clear all
Page 1
Malignant peritoneal mesothelioma.
Chun CP, Song LX, Zhang HP, Guo DD, Xu GX, Li Y, Xin X, Cao J, Li F. Chun CP, et al. Am J Med Sci. 2023 Jan;365(1):99-103. doi: 10.1016/j.amjms.2022.07.008. Epub 2022 Aug 6. Am J Med Sci. 2023. PMID: 35940275 Review.
As everyone knows, asbestos exposure is usually associated with pleural mesothelioma, but only 6%-10% of malignant mesothelioma cases originate from the peritoneum, which is far less than pleural mesothelioma. ...Patients should be vigilant, even thoug …
As everyone knows, asbestos exposure is usually associated with pleural mesothelioma, but only 6%-10% of malignant mesotheliom …
Advances in pleuroscopy.
Anevlavis S, Froudarakis ME. Anevlavis S, et al. Clin Respir J. 2018 Mar;12(3):839-847. doi: 10.1111/crj.12597. Epub 2017 Jan 11. Clin Respir J. 2018. PMID: 27997741 Review.
OBJECTIVES: To describe the technique of pleuroscopy, its clinical uses such as diagnosis of exudative pleural effusion, treatment of pleural infection, treatment of pneumothorax, and diagnosis and pleurodesis of malignant pleural mesothelioma. Also to describe the …
OBJECTIVES: To describe the technique of pleuroscopy, its clinical uses such as diagnosis of exudative pleural effusion, treatment of pleura …
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma.
Mencoboni M, Filiberti RA, Taveggia P, Grosso F, Pasello G, Del Corso L, Muzio A, Polo V, Zucali P, Ceresoli GL, Soto Parra HJ, Auriati L, Simonassi C. Mencoboni M, et al. Oncol Res Treat. 2017;40(6):364-369. doi: 10.1159/000464410. Epub 2017 May 9. Oncol Res Treat. 2017. PMID: 28472807 Review.
BACKGROUND: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. ...Median survival time was 11.6 months with supportive care, 16.2 months with chemotherapy only, 32.4 months with surgery plus chemotherapy, …
BACKGROUND: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. .. …
What's new in mesothelioma.
Ascoli V, Murer B, Nottegar A, Luchini C, Carella R, Calabrese F, Lunardi F, Cozzi I, Righi L. Ascoli V, et al. Pathologica. 2018 Mar;110(1):12-28. Pathologica. 2018. PMID: 30259910 Review.
Malignant pleural mesothelioma is a neoplasm characterized by a very poor prognosis and medico-legal implications. ...A nuclear grading system have been also proposed to stratify patient outcome. Reliable predictive biomarkers are still lacking in MPM and a p …
Malignant pleural mesothelioma is a neoplasm characterized by a very poor prognosis and medico-legal implications. ...A nuclea …
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, Maskell NA, Psallidas I. Bibby AC, et al. Eur Respir Rev. 2016 Dec;25(142):472-486. doi: 10.1183/16000617.0063-2016. Eur Respir Rev. 2016. PMID: 27903668 Free PMC article. Review.
Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos exposure. There is a global epidemic of malignant pleural mesothelioma underway, and incidence rates are predicted to peak …
Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos expo …
Genomics and Functional Genomics of Malignant Pleural Mesothelioma.
Cakiroglu E, Senturk S. Cakiroglu E, et al. Int J Mol Sci. 2020 Sep 1;21(17):6342. doi: 10.3390/ijms21176342. Int J Mol Sci. 2020. PMID: 32882916 Free PMC article. Review.
Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the mesothelial cells lining the pleural surface of the chest wall and lung. ...A better understanding of the molecular and cellular mechanisms and the predictors of poor clinical outcomes o …
Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the mesothelial cells lining the pleural surface of the c …
Biomarkers and prognostic factors for malignant pleural mesothelioma.
Vigneri P, Martorana F, Manzella L, Stella S. Vigneri P, et al. Future Oncol. 2015;11(24 Suppl):29-33. doi: 10.2217/fon.15.317. Future Oncol. 2015. PMID: 26638920 Review.
The increasing incidence and the dismal prognosis of malignant pleural mesothelioma calls for the identification of biomarkers that will allow a timely diagnosis; display prognostic value; and, predict the response to pharmacological agents employed for the t …
The increasing incidence and the dismal prognosis of malignant pleural mesothelioma calls for the identification of biomarkers …
"PET/CT Variants and Pitfalls in Lung Cancer and Mesothelioma".
Lopci E, Kobe C, Gnanasegaran G, Adam JA, de Geus-Oei LF. Lopci E, et al. Semin Nucl Med. 2021 Sep;51(5):458-473. doi: 10.1053/j.semnuclmed.2021.04.002. Epub 2021 May 11. Semin Nucl Med. 2021. PMID: 33993985 Review.
Used either at diagnosis or during treatment response assessment, the modality allows for a more accurate definition of tumor extent compared to morphological imaging and is able to predict the therapeutic benefit earlier in time. Due to the aspecific uptake property of [( …
Used either at diagnosis or during treatment response assessment, the modality allows for a more accurate definition of tumor extent compare …
The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma.
Perera ND, Mansfield AS. Perera ND, et al. Curr Oncol Rep. 2022 Nov;24(11):1413-1423. doi: 10.1007/s11912-022-01302-3. Epub 2022 Jun 3. Curr Oncol Rep. 2022. PMID: 35657483 Free PMC article. Review.
PURPOSE OF REVIEW: For patients with malignant pleural mesothelioma, prognosis is poor with extremely low 5-year survival rates and limited therapeutic options. ...The therapeutic landscape for malignant pleural mesothelioma is evolving and preferred t …
PURPOSE OF REVIEW: For patients with malignant pleural mesothelioma, prognosis is poor with extremely low 5-year survival rate …
Current surgical strategies for malignant pleural mesothelioma.
Takuwa T, Hasegawa S. Takuwa T, et al. Surg Today. 2016 Aug;46(8):887-94. doi: 10.1007/s00595-015-1275-3. Epub 2015 Nov 21. Surg Today. 2016. PMID: 26590581 Review.
Malignant pleural mesothelioma (MPM) is associated with a poor prognosis. The main components of multimodality treatment include surgery, chemotherapy, and radiation therapy. ...In our study, we review the advantages and disadvantages of EPP and P/D, summarize the p …
Malignant pleural mesothelioma (MPM) is associated with a poor prognosis. The main components of multimodality treatment inclu …
1,328 results